dr. overman on the impact of nivolumab in mcrc
Published 6 years ago • 129 plays • Length 1:42Download video MP4
Download video MP3
Similar videos
-
1:08
dr. overman discusses nivolumab in patients with dmmr/msi h mcrc
-
1:03
dr. overman on implications of tumor location data for patients with mcrc
-
2:00
dr. overman on nivolumab and ipilimumab in patients with msi-h crc
-
1:24
dr. overman on updated findings with nivolumab in metastatic crc
-
1:37
dr. overman on next steps with immunotherapy in mcrc
-
1:46
dr. overman on investigational targeted therapies in mcrc
-
2:32
dr. overman discusses updated findings of checkmate-142 in patients with msi-h mcrc
-
1:29
dr. overman on tailoring approaches to molecular subsets in mcrc
-
1:05
nivolumab and ipilimumab combination in frontline mcrc
-
1:18
dr. overman on unmet needs with immunotherapy in mcrc
-
5:19
i-o therapy in mcrc: ipilimumab nivolumab
-
1:28
dr. overman on distinctions between regorafenib and tas-102 in crc
-
2:15
dr. overman discusses redos study in mcrc
-
1:31
dr. michael j. overman on immunotherapy in colorectal cancer
-
1:22
dr. overman on potential applications of ctdna in colorectal cancer
-
1:43
nivolumab, ipilimumab and panitumumab in mcrc
-
2:03
promising checkmate-142 data for second-line ipilimumab plus nivolumab in mcrc
-
1:09
dr. overman on second-line therapy options for colorectal cancer
-
1:11
remaining questions for the treatment of patients with msi/dmmr mcrc with immunotherapy